At a glance
- Originator GlaxoSmithKline
- Class Anxiolytics
- Mechanism of Action Serotonin 2B receptor antagonists; Serotonin 2C receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 13 Aug 1996 Discontinued-Preclinical for Anxiety disorders in United Kingdom (Unknown route)
- 18 Dec 1995 New profile
- 18 Dec 1995 Preclinical development for Anxiety disorders in United Kingdom (Unknown route)